May 01, 2025

Health Care Faces New Immigration Reality

Health care facilities face new challenges as sensitive locations policy protecting them from immigration enforcement was rescinded in January 2025, requiring new protocols for patient protection.

Conexiant

April 30, 2025

New Phase III Data on Brensocatib Therapy

Phase III trial results show that once-daily brensocatib reduces pulmonary exacerbations and slows lung function decline in patients with bronchiectasis.

Conexiant

April 30, 2025

New Phase III Data: Sotatercept for PAH

Sotatercept reduced the composite risk of death, lung transplantation, or hospitalization for worsening pulmonary arterial hypertension by nearly 75% compared with placebo in high-risk patients in a phase III trial.

Conexiant

April 29, 2025

New Oral Option Approved for GCA

The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.

Conexiant

April 29, 2025

AACR 2025: Oral HER2-Targeted Therapy for Advanced HER2-Mutated Lung Cancer

The novel HER2-targeted tyrosine kinase inhibitor zongertinib elicited durable responses in patients with advanced, previously treated non–small cell lung cancer (NSCLC) that harbored a HER2 mutation,...

The ASCO Post

April 25, 2025

FDA Approves Penpulimab-kcqx for NPC

The FDA approved penpulimab-kcqx for first line and previously treated recurrent or metastatic non-keratinizing nasopharyngeal carcinoma.

Conexiant

April 23, 2025

Sense of Belonging 'Critical' for Workplace Retention

Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.

Conexiant

April 21, 2025

Therapy With a Tyrosine Kinase Inhibitor for EGFR-Variant Lung Adenocarcinoma: Lessons From Chronic Myeloid Leukemia?

In a recent article, the use of tyrosine kinase inhibitors in treating EGFR-variant lung adenocarcinoma is explored, drawing comparisons to their use in chronic myeloid leukemia, highlighting similarities and differences.

The ASCO Post

April 21, 2025

Transfusion Strategy Outcomes After Aneurysmal SAH Similar, Study Reveals

SAHaRA trial investigators compared a liberal (transfusion at hemoglobin levels of 10 g/dL or lower) and a restrictive (transfusion at 8 g/dL or lower) red-cell tranfusion strategy among critically ill patients with acute aneurysmal subarachnoid hemorrhage (SAH) and anemia.

Conexiant